What are the next steps for a 45-year-old man who has sex with men (MSM) and is living with Human Immunodeficiency Virus (HIV), who recently received an anal Pap smear result showing Atypical Squamous Cells of Undetermined Significance (ASC-US)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of ASC-US on Anal Pap Smear in HIV-Positive MSM

For a 45-year-old MSM patient with HIV who has an anal Pap smear showing ASC-US, the recommended next step is to repeat anal cytology in 4-6 months, with referral for high-resolution anoscopy (HRA) if a second ASC-US or higher-grade abnormality is detected within a 2-year follow-up period.

Understanding the Result

The patient's anal Pap smear shows Atypical Squamous Cells of Undetermined Significance (ASC-US), which represents:

  • A low-grade abnormality that requires follow-up
  • A finding that indicates possible HPV infection but is not diagnostic of dysplasia
  • A result that warrants structured surveillance due to the patient's high-risk status (HIV-positive MSM)

Recommended Management Algorithm

Initial Management

  • Repeat anal cytology every 4-6 months for 2 years until three consecutive negative smears are obtained 1
  • If the transformation zone was not present in the initial sample (as noted in the result), ensure proper sampling technique for follow-up tests

Indications for High-Resolution Anoscopy (HRA)

  • Second report of ASC-US within the 2-year follow-up period 1
  • Any higher-grade abnormality (LSIL, HSIL) on subsequent testing
  • Presence of severe inflammation associated with the ASC-US finding (evaluate for infectious process first) 1
  • Poor expected adherence to follow-up schedule 1

Rationale for Recommendations

HIV-positive MSM are at significantly increased risk for:

  • Anal HPV infection (detected in up to 93% of HIV-positive MSM) 2
  • Development of anal intraepithelial neoplasia (AIN) 3
  • Progression to anal cancer 4

The sensitivity of anal cytology for detecting high-grade AIN is approximately 84%, with a negative predictive value of 88% 2. This supports the value of regular screening and follow-up in this high-risk population.

Important Considerations

  • Time to follow-up matters: Studies show that only 24.3% of PLWH have HRA within 6 months after an abnormal anal cytology, and only 57% within 12 months 5. Emphasize the importance of adherence to follow-up schedule.
  • Potential pitfalls: Atypical parakeratotic cells can lead to false-positive results 6. Histologic confirmation via HRA-guided biopsy is the gold standard for definitive diagnosis.
  • Risk factors for progression: Multiple HPV types, especially high-risk types, and HIV infection are independently associated with ASIL 3.

Alternative Approaches

Some experts advocate for more aggressive management in HIV-positive individuals:

  • Immediate referral for HRA regardless of cytology grade due to high prevalence of high-grade lesions in this population 4
  • HPV DNA testing as an adjunct to cytology, which has shown 100% sensitivity but only 16% specificity for detecting AIN 2+ 2

However, based on current guidelines, the structured follow-up approach with repeat cytology remains the standard of care for ASC-US findings in this population 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.